Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irradiated MMC10-AD whole tumor cell vaccine is an experimental, preclinical whole-cell cancer vaccine derived from the MMC10-AD mouse mammary carcinoma cell line. The MMC10-AD cell line is established by culturing spontaneous breast tumor cells from Her-2/neu transgenic mice in standard, adherent (AD) serum-containing conditions. The vaccine consists of these cells after they have been lethally irradiated. In preclinical research, it is utilized to study immune tolerance and evaluate the priming of CD4+ and CD8+ neu-reactive T cells, often serving as a comparative control to vaccines derived from breast cancer stem-like cells (MMC10-BCSC).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on irradiated MMC10-AD whole tumor cell vaccine.